NO317427B1 - Sammensetning med hoy renhet omfattende (7<alfa>, 17<alfa>)-17-hydroksy-7-metyl-19-nor-17-pregn-5(10)-en-20-yn-3-on - Google Patents

Sammensetning med hoy renhet omfattende (7<alfa>, 17<alfa>)-17-hydroksy-7-metyl-19-nor-17-pregn-5(10)-en-20-yn-3-on Download PDF

Info

Publication number: NO317427B1
Authority: NO; Norway
Prior art keywords: hydroxy; methyl; pregn; less; amount
Prior art date: 1998-10-16

Application number

NO20011664A

Other languages

English (en)

Norwegian (no)

Other versions

NO20011664D0 (no

NO20011664L (no

Inventor

Peter Huub Gerard Kirchholtes

Gerard Arnoud Jozef Maria Sas

Original Assignee

Akzo Nobel Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-16

Filing date

2001-04-03

Publication date

2004-10-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8234220&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO317427(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-04-03 Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv

2001-04-03 Publication of NO20011664D0 publication Critical patent/NO20011664D0/no

2001-04-03 Publication of NO20011664L publication Critical patent/NO20011664L/no

2004-10-25 Publication of NO317427B1 publication Critical patent/NO317427B1/no

Links

239000000203 mixture Substances 0.000 title claims description 45
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
150000001875 compounds Chemical class 0.000 claims description 22
239000013078 crystal Substances 0.000 claims description 16
238000000034 method Methods 0.000 claims description 14
239000007787 solid Substances 0.000 claims description 9
238000002156 mixing Methods 0.000 claims description 7
238000009472 formulation Methods 0.000 claims description 6
239000008194 pharmaceutical composition Substances 0.000 claims description 6
230000015572 biosynthetic process Effects 0.000 claims description 5
230000032683 aging Effects 0.000 claims description 3
239000003960 organic solvent Substances 0.000 claims description 3
238000003786 synthesis reaction Methods 0.000 claims description 3
230000002378 acidificating effect Effects 0.000 claims description 2
238000006243 chemical reaction Methods 0.000 claims description 2
239000000243 solution Substances 0.000 claims description 2
239000007864 aqueous solution Substances 0.000 claims 1
238000005406 washing Methods 0.000 claims 1
WZDGZWOAQTVYBX-XOINTXKNSA-N tibolone Chemical compound C([C@@H]12)C[C@]3(C)[C@@](C#C)(O)CC[C@H]3[C@@H]1[C@H](C)CC1=C2CCC(=O)C1 WZDGZWOAQTVYBX-XOINTXKNSA-N 0.000 description 37
229960001023 tibolone Drugs 0.000 description 36
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 26
101000764229 Rattus norvegicus Mitochondrial import receptor subunit TOM40 homolog Proteins 0.000 description 21
239000003826 tablet Substances 0.000 description 16
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 15
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 13
238000003860 storage Methods 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 11
239000008187 granular material Substances 0.000 description 11
238000004519 manufacturing process Methods 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
238000001035 drying Methods 0.000 description 6
239000002775 capsule Substances 0.000 description 5
239000012535 impurity Substances 0.000 description 5
235000006408 oxalic acid Nutrition 0.000 description 5
239000000725 suspension Substances 0.000 description 5
239000000843 powder Substances 0.000 description 4
238000005550 wet granulation Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
239000012530 fluid Substances 0.000 description 3
238000005469 granulation Methods 0.000 description 3
230000003179 granulation Effects 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
229920001592 potato starch Polymers 0.000 description 3
230000035882 stress Effects 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000006317 isomerization reaction Methods 0.000 description 2
239000008101 lactose Substances 0.000 description 2
230000007774 longterm Effects 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000002904 solvent Substances 0.000 description 2
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
229920000715 Mucilage Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
230000001548 androgenic effect Effects 0.000 description 1
235000010385 ascorbyl palmitate Nutrition 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
229960005215 dichloroacetic acid Drugs 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000007908 dry granulation Methods 0.000 description 1
230000001076 estrogenic effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
-1 for example Substances 0.000 description 1
230000002431 foraging effect Effects 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229920001903 high density polyethylene Polymers 0.000 description 1
239000004700 high-density polyethylene Substances 0.000 description 1
230000002519 immonomodulatory effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000004898 kneading Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
230000016087 ovulation Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000000757 progestagenic effect Effects 0.000 description 1
238000007873 sieving Methods 0.000 description 1
239000002002 slurry Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
238000001291 vacuum drying Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0081—Substituted in position 17 alfa and 17 beta
- C07J1/0088—Substituted in position 17 alfa and 17 beta the substituent in position 17 alfa being an unsaturated hydrocarbon group
- C07J1/0096—Alkynyl derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Reproductive Health (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Immunology (AREA)
Biophysics (AREA)
Pregnancy & Childbirth (AREA)
Gynecology & Obstetrics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Steroid Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

NO20011664A 1998-10-16 2001-04-03 Sammensetning med hoy renhet omfattende (7<alfa>, 17<alfa>)-17-hydroksy-7-metyl-19-nor-17-pregn-5(10)-en-20-yn-3-on NO317427B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP98203460		1998-10-16
PCT/EP1999/007768 WO2000023460A1 (fr)	1998-10-16	1999-10-11	COMPOSITION A DEGRE ELEVE DE PURETE RENFERMANT (7α,17α)-17-HYDROXY-7-METHYL-19-NOR-17-PREGN-5(10)-EN-20-YN-3-ONE

Publications (3)

Publication Number	Publication Date
NO20011664D0 NO20011664D0 (no)	2001-04-03
NO20011664L NO20011664L (no)	2001-04-03
NO317427B1 true NO317427B1 (no)	2004-10-25

Family

ID=8234220

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20011664A NO317427B1 (no)	1998-10-16	2001-04-03	Sammensetning med hoy renhet omfattende (7<alfa>, 17<alfa>)-17-hydroksy-7-metyl-19-nor-17-pregn-5(10)-en-20-yn-3-on

Country Status (30)

Country	Link
US (3)	US6969708B1 (fr)
EP (2)	EP1275379A3 (fr)
JP (1)	JP2002527525A (fr)
KR (3)	KR100635018B1 (fr)
CN (2)	CN100378116C (fr)
AR (1)	AR020832A1 (fr)
AT (1)	ATE239032T1 (fr)
AU (1)	AU763232B2 (fr)
BR (1)	BR9914441A (fr)
CA (1)	CA2344686C (fr)
CO (1)	CO5160271A1 (fr)
CZ (1)	CZ298703B6 (fr)
DE (1)	DE69907495T2 (fr)
DK (1)	DK1121375T3 (fr)
ES (1)	ES2197677T3 (fr)
HK (1)	HK1039620B (fr)
HU (1)	HUP0104206A3 (fr)
ID (1)	ID28463A (fr)
IL (1)	IL141850A (fr)
NO (1)	NO317427B1 (fr)
NZ (1)	NZ510501A (fr)
PE (1)	PE20001377A1 (fr)
PL (1)	PL197870B1 (fr)
PT (1)	PT1121375E (fr)
RU (1)	RU2220975C2 (fr)
SK (1)	SK284569B6 (fr)
TR (2)	TR200101083T2 (fr)
TW (2)	TW200403251A (fr)
WO (1)	WO2000023460A1 (fr)
ZA (1)	ZA200101952B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL356465A1 (en) *	2002-10-04	2004-04-05	ANPHARM Przedsiębiorstwo Farmaceutyczne S.A.	METHOD OF MANUFACTURE OF 17beta-HYDROXY-7alpha-METHYL-19-NOR-17alpha-PREGN-5(10)-ENE-20-YNE-3-ONE
TW200418525A (en) *	2002-11-20	2004-10-01	Akzo Nobel Nv	Coated pharmaceutical tablets containing Tibolone
GB0304927D0 (en)	2003-03-04	2003-04-09	Resolution Chemicals Ltd	Process for the production of tibolone
WO2005117899A1 (fr) *	2004-06-02	2005-12-15	Cipla Limited	Composition pharmaceutique comprenant de la tibolone et son procede de production
KR100908529B1 (ko) *	2005-02-01	2009-07-20	에프. 호프만-라 로슈 아게	이반드로네이트 다형체 에이
EP1848727B1 (fr)	2005-02-01	2015-06-17	F.Hoffmann-La Roche Ag	Polymorphe b d'ibandronate
WO2006125453A1 (fr) *	2005-05-23	2006-11-30	Newchem S.P.A.	Procede de preparation de tibolone cristalline pure
CZ300465B6 (cs) *	2007-07-25	2009-05-27	Zentiva, A. S.	Zpusob výroby komprimované farmaceutické formulace s obsahem tibolonu
ITMI20130120A1 (it) *	2013-01-25	2014-07-26	Ind Chimica Srl	Processo per la preparazione in forma cristallina di tibolone, (7alfa,17alfa)-17-idrossi-7-metil-19-norpregn-5(10)-en-20-in-3-one
US20220046948A1 (en) *	2018-12-17	2022-02-17	Aimmune Therapeutics, Inc.	Formulations for egg oral immunotherapy, methods of manufacture, and treatments for egg allergy
CN114409717B (zh) *	2021-12-17	2023-03-17	湖南科益新生物医药有限公司	替勃龙中间体醚化物和替勃龙的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE665514A (fr)	1964-06-16
CH488682A (de)	1965-07-30	1970-04-15	Ciba Geigy	Verfahren zur Herstellung von 4,9,11-Trienen der 19-Nor-androstanreihe
NL146838B (nl)	1966-06-24	1975-08-15	Organon Nv	Werkwijze voor het bereiden van (delta)5(10)-3- keto-19-norsteroiden.
US3515719A (en)	1967-03-15	1970-06-02	Upjohn Co	7-methyl-6,19-epoxy steroids of the androstane series
US4701450A (en) *	1984-03-21	1987-10-20	Akzo N.V.	Steroids for use as immunomodulators
EP0406279A1 (fr)	1988-03-25	1991-01-09	Akzo N.V.	Preparation pharmaceutique contenant un sel de fluorure
IE63051B1 (en)	1989-03-18	1995-03-22	Akzo Nv	Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn- 3-one
DK0613687T3 (da) *	1993-03-05	1999-12-06	Akzo Nobel Nv	Anvendelse af pregnanderivat til behandling af tumorer
IL115445A (en) *	1994-10-17	1999-08-17	Akzo Nobel Nv	Solid pharmaceutical compositions comprising low dosage active ingredient oil and excipient capable of binding water and their preparation
TW448049B (en)	1997-03-05	2001-08-01	Akzo Nobel Nv	Use of a 7Α-methyl-17Α-ethynyl-estrane derivative for the treatment of atherosclerosis
IL123984A (en) *	1997-04-22	2004-09-27	Akzo Nobel Nv	Pharmacological dosage units containing tibolone and carrier pharmacy are acceptable

1999
- 1999-10-11 TR TR2001/01083T patent/TR200101083T2/xx unknown
- 1999-10-11 US US09/787,215 patent/US6969708B1/en not_active Expired - Fee Related
- 1999-10-11 EP EP02022689A patent/EP1275379A3/fr not_active Withdrawn
- 1999-10-11 CN CNB99811734XA patent/CN100378116C/zh not_active Expired - Fee Related
- 1999-10-11 ES ES99948994T patent/ES2197677T3/es not_active Expired - Lifetime
- 1999-10-11 EP EP99948994A patent/EP1121375B1/fr not_active Revoked
- 1999-10-11 PL PL347264A patent/PL197870B1/pl not_active IP Right Cessation
- 1999-10-11 AT AT99948994T patent/ATE239032T1/de not_active IP Right Cessation
- 1999-10-11 HU HU0104206A patent/HUP0104206A3/hu unknown
- 1999-10-11 TR TR2005/04091T patent/TR200504091T2/xx unknown
- 1999-10-11 WO PCT/EP1999/007768 patent/WO2000023460A1/fr active IP Right Grant
- 1999-10-11 DE DE69907495T patent/DE69907495T2/de not_active Revoked
- 1999-10-11 KR KR1020017004639A patent/KR100635018B1/ko not_active IP Right Cessation
- 1999-10-11 ID IDW20010850A patent/ID28463A/id unknown
- 1999-10-11 BR BR9914441-7A patent/BR9914441A/pt not_active Application Discontinuation
- 1999-10-11 CZ CZ20010976A patent/CZ298703B6/cs not_active IP Right Cessation
- 1999-10-11 TW TW092128164A patent/TW200403251A/zh unknown
- 1999-10-11 TW TW088117530A patent/TW577893B/zh not_active IP Right Cessation
- 1999-10-11 NZ NZ510501A patent/NZ510501A/en not_active IP Right Cessation
- 1999-10-11 DK DK99948994T patent/DK1121375T3/da active
- 1999-10-11 IL IL14185099A patent/IL141850A/xx not_active IP Right Cessation
- 1999-10-11 AU AU62029/99A patent/AU763232B2/en not_active Expired
- 1999-10-11 KR KR10-2004-7016210A patent/KR20050003358A/ko not_active Application Discontinuation
- 1999-10-11 JP JP2000577186A patent/JP2002527525A/ja not_active Withdrawn
- 1999-10-11 SK SK493-2001A patent/SK284569B6/sk not_active IP Right Cessation
- 1999-10-11 CN CNB2005101186668A patent/CN100432093C/zh not_active Expired - Fee Related
- 1999-10-11 RU RU2001113281/04A patent/RU2220975C2/ru not_active IP Right Cessation
- 1999-10-11 PT PT99948994T patent/PT1121375E/pt unknown
- 1999-10-11 CA CA002344686A patent/CA2344686C/fr not_active Expired - Fee Related
- 1999-10-11 KR KR1020067011204A patent/KR20060071897A/ko not_active Application Discontinuation
- 1999-10-15 PE PE1999001042A patent/PE20001377A1/es not_active Application Discontinuation
- 1999-10-15 CO CO99065751A patent/CO5160271A1/es unknown
- 1999-10-15 AR ARP990105229A patent/AR020832A1/es unknown
2001
- 2001-03-08 ZA ZA200101952A patent/ZA200101952B/en unknown
- 2001-04-03 NO NO20011664A patent/NO317427B1/no not_active IP Right Cessation
2002
- 2002-01-18 HK HK02100410.0A patent/HK1039620B/zh not_active IP Right Cessation
2004
- 2004-07-08 US US10/887,397 patent/US20040248870A1/en not_active Abandoned
2005
- 2005-07-07 US US11/176,842 patent/US20050245496A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU763232B2 (en)	2003-07-17
CN1769293A (zh)	2006-05-10
CN100432093C (zh)	2008-11-12
CA2344686A1 (fr)	2000-04-27
HUP0104206A2 (hu)	2002-04-29
PL197870B1 (pl)	2008-05-30
US20050245496A1 (en)	2005-11-03
CN1322210A (zh)	2001-11-14
PL347264A1 (en)	2002-03-25
NZ510501A (en)	2003-10-31
AU6202999A (en)	2000-05-08
ID28463A (id)	2001-05-24
KR20050003358A (ko)	2005-01-10
NO20011664D0 (no)	2001-04-03
HK1039620B (zh)	2003-08-22
EP1275379A3 (fr)	2003-03-26
CN100378116C (zh)	2008-04-02
KR20060071897A (ko)	2006-06-27
HK1039620A1 (en)	2002-05-03
CO5160271A1 (es)	2002-05-30
EP1121375A1 (fr)	2001-08-08
BR9914441A (pt)	2001-06-26
EP1275379A2 (fr)	2003-01-15
TR200101083T2 (tr)	2001-08-21
US6969708B1 (en)	2005-11-29
SK4932001A3 (en)	2001-12-03
CZ2001976A3 (cs)	2001-08-15
TW200403251A (en)	2004-03-01
TW577893B (en)	2004-03-01
AR020832A1 (es)	2002-05-29
CA2344686C (fr)	2009-04-28
WO2000023460A1 (fr)	2000-04-27
US20040248870A1 (en)	2004-12-09
JP2002527525A (ja)	2002-08-27
PT1121375E (pt)	2003-07-31
TR200504091T2 (tr)	2006-05-22
HUP0104206A3 (en)	2002-06-28
IL141850A0 (en)	2002-03-10
IL141850A (en)	2005-11-20
NO20011664L (no)	2001-04-03
DK1121375T3 (da)	2003-08-04
DE69907495T2 (de)	2004-05-06
KR20010080133A (ko)	2001-08-22
CZ298703B6 (cs)	2007-12-27
SK284569B6 (sk)	2005-06-02
ES2197677T3 (es)	2004-01-01
RU2220975C2 (ru)	2004-01-10
KR100635018B1 (ko)	2006-10-17
ATE239032T1 (de)	2003-05-15
PE20001377A1 (es)	2000-12-09
ZA200101952B (en)	2002-06-10
DE69907495D1 (de)	2003-06-05
EP1121375B1 (fr)	2003-05-02

Legal Events

Date	Code	Title	Description
2012-06-04	MM1K	Lapsed by not paying the annual fees

Publication	Publication Date	Title
US20050245496A1 (en)	2005-11-03	High-purity composition comprising (7a,17a)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one and a process for purifying (7a,17a)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one
AU2002227421B2 (en)	2007-08-23	Steroid hormone products comprising a stabilizing agent in non-crystalline form
HU226619B1 (en)	2009-04-28	Process of making dosage units containing at least one progestogen by wet granulation
KR0177493B1 (ko)	1999-03-20	단사정계 결정구조를 갖고 감열, 감광 및 감습성이 있는 활성성분을 함유하는 정제의 제조방법
US4666919A (en)	1987-05-19	Stabilized pharmaceutical composition containing an isocarbostyril derivative
US20030186956A1 (en)	2003-10-02	Process for drying amoxicillin
MXPA01003797A (en)	2001-12-04	HIGH PURITY COMPOSITION COMPRISING (7&agr;,17&agr;)- 17-HYDROXY- 7-METHYL- 19-NOR-17-PREGN- 5(10)-EN-20-YN-3-ONE
NO780799L (no)	1978-09-15	Fremgangsmaate til fremstilling av et fast steroid-preparat
CN115487198B (zh)	2024-01-02	一种快溶出度的左炔诺孕酮制剂及其制备方法
MXPA04011796A (es)	2005-03-31	Unidades de dosificacion progestagenica.
EP2182955A2 (fr)	2010-05-12	Procédé de fabrication de formulation pharmaceutique comprimée contenant de la tibolone
WO2005084682A1 (fr)	2005-09-15	Composition pharmaceutique comprenant un complexe cyclodextrine de tibolone
CZ374299A3 (cs)	2000-04-12	Farmaceutická léková forma